1. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
- Author
-
Fu Fei Hsu, Chu Chi Lin, Cheng Chin Chiang, Yunching Chen, Yu-Ting Huang, Chih-Chun Chang, Jiantai Timothy Qiu, Hsi Chien Huang, Trinh Kieu Dinh, Guann Jen Chern, Yun Chieh Sung, Kuan Wei Huang, Rui Lin Huang, Yi An Lee, Yung-Chang Lin, Shu-Yi Lin, Donia Alson, Chun-Yen Lin, Yu Chuan Shih, and Po Chiao Chang
- Subjects
Calcium Phosphates ,Male ,medicine.medical_treatment ,02 engineering and technology ,Theranostic Nanomedicine ,Mice ,Antineoplastic Agents, Immunological ,Drug Delivery Systems ,Cancer immunotherapy ,Neoplasms ,Medicine ,Nanotechnology ,Molecular Targeted Therapy ,Immunogenetic Phenomena ,RNA, Small Interfering ,Research Articles ,Cancer ,0303 health sciences ,Multidisciplinary ,Gene Transfer Techniques ,food and beverages ,SciAdv r-articles ,021001 nanoscience & nanotechnology ,Lipids ,Stimulator of interferon genes ,Cytokines ,Immunotherapy ,0210 nano-technology ,Research Article ,Plasmids ,Signal Transduction ,Immunology ,Immunopotentiator ,Gene delivery ,03 medical and health sciences ,Biomarkers, Tumor ,Animals ,Humans ,030304 developmental biology ,Tumor microenvironment ,business.industry ,fungi ,Membrane Proteins ,Dendritic Cells ,Genetic Therapy ,Immune checkpoint ,Cancer research ,Nanoparticles ,Cancer vaccine ,business ,Biomarkers - Abstract
The dual-targeted immunogene therapy that inhibits PD-L1 and provides IL-2 can enhance the therapeutic efficacy of cancer vaccine., While immunotherapy holds great promise for combating cancer, the limited efficacy due to an immunosuppressive tumor microenvironment and systemic toxicity hinder the broader application of cancer immunotherapy. Here, we report a combinatorial immunotherapy approach that uses a highly efficient and tumor-selective gene carrier to improve anticancer efficacy and circumvent the systemic toxicity. In this study, we engineered tumor-targeted lipid-dendrimer-calcium-phosphate (TT-LDCP) nanoparticles (NPs) with thymine-functionalized dendrimers that exhibit not only enhanced gene delivery capacity but also immune adjuvant properties by activating the stimulator of interferon genes (STING)–cGAS pathway. TT-LDCP NPs delivered siRNA against immune checkpoint ligand PD-L1 and immunostimulatory IL-2–encoding plasmid DNA to hepatocellular carcinoma (HCC), increased tumoral infiltration and activation of CD8+ T cells, augmented the efficacy of cancer vaccine immunotherapy, and suppressed HCC progression. Our work presents nanotechnology-enabled dual delivery of siRNA and plasmid DNA that selectively targets and reprograms the immunosuppressive tumor microenvironment to improve cancer immunotherapy.
- Published
- 2020